AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multi
Positive Phase 3 data show etentamig improved response and survival in relapsed myeloma.
What changed
Positive Phase 3 data show etentamig improved response and survival in relapsed myeloma.
Why it matters
Positive Phase 3 data show etentamig improved response and survival in relapsed myeloma. — impact context not separately stored; see What changed.
← Dashboard
Sep 03, 2026 02:05 PM ET